[144] BIOLIFE SOLUTIONS INC SEC Filing

Rhea-AI Filing Summary

BIOLIFE SOLUTIONS, INC. (BLFS) Rule 144 notice reports proposed sale of 714 common shares by a holder through Morgan Stanley Smith Barney on 09/15/2025 on NASDAQ, with an aggregate market value listed as $18,214.14 and total shares outstanding shown as 47,905,265. The securities were acquired as restricted stock units on 09/08/2025 from the issuer and the filing records payment or settlement on that same date.

The filer disclosed three prior sales by the same person in the past three months: 711 shares via a 10b5-1 sale on 06/16/2025 for $15,805.53, 198 shares on 07/07/2025 for $4,409.46, and 219 shares on 08/26/2025 for $5,571.36. The filing includes a representation that the seller is not aware of undisclosed material adverse information and notes the option to rely on a 10b5-1 plan; no plan adoption date or signature block details are present in the provided content.

Positive

• Disclosure of broker and sale details (Morgan Stanley Smith Barney, NASDAQ, sale date 09/15/2025) provides transparency
• Prior 10b5-1 sale is identified, indicating use of a prearranged trading plan for at least one transaction
• Sales represent a small fraction of the reported 47,905,265 shares outstanding, suggesting limited market impact

Negative

• Insider selling shares (714 proposed plus 1,128 sold in prior three months) could be viewed negatively by some investors
• Plan adoption date and signature details not present in the provided excerpt, limiting confirmation of procedural compliance

Insights

Securities Analyst

TL;DR: Insider sale of 714 RSU-derived shares planned; prior small sales this quarter; disclosure appears procedural and routine.

The filing documents a proposed Rule 144 sale of 714 common shares with an indicated market value of $18,214.14 executed through Morgan Stanley Smith Barney on NASDAQ. The shares were acquired as restricted stock units from the issuer on 09/08/2025 and appear settled the same day. Prior sales by the same person total 1,128 shares across three transactions in the past three months, including a 10b5-1 sale of 711 shares. These volumes represent a very small fraction of the reported 47,905,265 shares outstanding, suggesting limited direct dilution or market impact from these sales. The notice includes the Rule 144 representation regarding material non-public information; however, no plan adoption date is provided in the content supplied.

Compliance / Corporate Governance Specialist

TL;DR: Filing contains required Rule 144 and 10b5-1 disclosures; appears compliant though plan/signature details are not included in the excerpt.

The submission lists broker details, sale date, class, and acquisition method consistent with Form 144 requirements. It also discloses recent sales including a specifically labeled 10b5-1 sale, which supports an orderly-trading defense if accurate. The filing asserts the seller lacks undisclosed material adverse information. The excerpt does not show the signature block or an explicit 10b5-1 plan adoption date, which are relevant for compliance verification; those items may exist elsewhere in the full filing but are not present here.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	714	18214.14	47905265	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Restricted Stock Units	Issuer			714	09/08/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SARAH AEBERSOLD 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	08/26/2025	219	5571.36
SARAH AEBERSOLD 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	07/07/2025	198	4409.46
10b5-1 Sales for SARAH AEBERSOLD 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	06/16/2025	711	15805.53

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for BLFS report?

The form reports a proposed Rule 144 sale of 714 common shares through Morgan Stanley Smith Barney on 09/15/2025 with aggregate market value $18,214.14.

How were the 714 shares acquired?

The shares were acquired as restricted stock units from the issuer on 09/08/2025 and the filing lists the same date for settlement/payment.

Has the seller conducted recent sales of BLFS shares?

Yes. The filing lists three sales in the past three months: 711 shares on 06/16/2025 (10b5-1) for $15,805.53, 198 shares on 07/07/2025 for $4,409.46, and 219 shares on 08/26/2025 for $5,571.36.

Does the filing state the seller possesses any undisclosed material information?

The filer represents that the seller does not know any material adverse information about the issuer that has not been publicly disclosed.

Is there a 10b5-1 plan adoption date provided?

No. The provided content does not include a plan adoption date or detailed signature information.